Table 1

Baseline characteristics of strokes and stroke mimics treated with intravenous thrombolysis treatment

StrokesStroke mimics
No./totalMedian (IQR) or proportionNo./totalMedian (IQR) or proportionp Value
Age, year62572 (64–81)4854 (40–67)<0.0001
Age≤40 years11/6252%12/4825%<0.0001
Sex, female290/62646%19/4837.5%0.3
Previous stroke or TIA162/62626%12/4825%1.0
Hypertension300/60949%12/4825%0.001
Diabetes mellitus86/60614%5/4711%0.7
Hyperlipidaemia44/6057%2/474.3%0.8
Atrial fibrillation128/60621%4/478.5%0.04
mRS 0–1 before stroke556/62689%45/4894%0.5
NIHSS5486 (3–11)475 (3–9)0.8
Prior antihypertensive357/62657%13/4828%<0.0001
Prior antiplatelet/anticoagulant301/62548%13/4728%0.006
Prior statin155/62625%6/4812.5%0.06
Systolic blood pressure575155 (140–169)47144 (132–155)0.04
Diastolic blood pressure57580 (70–90)4784 (79–96)0.1
Door-needle time, min61958 (47–75)4856.5 (45–73)1.0
Time stroke onset-rTPA, min617135 (104–180)48120 (91–191)0.5
Serum glucose, mmol/L5626.5 (5.8–7.7)436.1 (5.5–6.8)0.1
Serum cholesterol, mmol/L4704.9 (4.3–5.8)375.2 (4.6–5.8)0.08
Serum LDL, mmol/L4562.9 (2.3–3.7)363.1 (2.4–3.5)0.3
Serum HDL, mmol/L4661.3 (1.1–1.6)381.3 (1.1–1.7)0.9
INR5751.0 (1.0–1.1)471.0 (1.0–1.1)1.0
Blood platelet count (×109/L)583224 (188–268)47226 (192–245)0.9
Creatinine, µmol/L58083 (69–96)4575 (65–83)0.001
High-sensitive CRP5802 (1–6)462 (0–4)0.3
Adminstered dose rTPA, mg59967 (58–76)4568 (58–76)0.9
BMI, kg m258225 (23–28)4726 (21–29)0.6
  • BMI, body mass index; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; TIA, transitory ischaemic attacks.